GlassScriptPhysician profile
Gilberto Acosta
NPI 1669475356
$6,393.79
in general payments reported to CMS, 2019-2025
48 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $526 · 2021: $1,663 · 2022: $721 · 2023: $616 · 2024: $1,261 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.34 | 2021-2025 | Botox, Ubrelvy |
| Boston Scientific Corporation | $657.28 | 2019-2025 | Intracept, Intracept Rf Probe, General - Pain Management |
| Medtronic, INC. | $608.69 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Nutech Spine, INC. | $528.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $310.03 | 2019-2025 | Xtampza, Belbuca |
| Vgi Medical, LLC | $307.48 | 2022 | |
| Tersera Therapeutics LLC | $272.61 | 2019-2025 | Prialt |
| Scilex Pharmaceuticals INC. | $252.64 | 2019-2024 | Ztlido |
| Allergan, INC. | $233.92 | 2019-2022 | |
| Nevro Corp. | $212.44 | 2019-2024 | Senza |
| Spinefrontier, INC. | $164.80 | 2025 | Inspan, Facetfuse, Sijfuse |
| Teva Pharmaceuticals USA, INC. | $155.89 | 2019-2020 | |
| Pfizer INC. | $155.11 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.27 | 2019-2023 | Relistor |
| Novartis Pharmaceuticals Corporation | $133.29 | 2019-2021 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.